SCHEMBL20119362

SCHEMBL20119362

Fc1c[nH]c2nc(Cl)nc(NCc3ccncc3)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.40
APP P05067 1/20 0.40
PDE10A Q9Y233 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
ESR1 P03372 5/20 0.38
KCNH3 Q9ULD8 1/20 0.38
CHUK O15111 1/20 0.38
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
ROCK2 O75116 1/20 0.36
GRK2 P25098 1/20 0.36
PLAU P00749 1/20 0.36
PDE2A O00408 1/20 0.36
CDK2 P24941 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119883 0.88 PDE5A (0.40) PDE5AAPPPDE10AADORA2AADORA1
SCHEMBL20119884 0.85 ESR1 (0.44) PDE5AAPPPDE10AADORA2AADORA1
SCHEMBL20120101 0.82 ESR1 (0.40) PDE5AAPPESR1CHUKPDE2A
SCHEMBL20119636 0.82 CHUK (0.59) PDE5AAPPPDE10AADORA2AADORA1
SCHEMBL20119892 0.82 KCNH3 (0.43) KCNH3PDE2ACDK2
SCHEMBL20119714 0.81 VNN1 (0.42) PDE5AAPPESR1ALDH1A1
SCHEMBL20344024 0.79 ESR1 (0.56) PDE5AAPPADORA2AADORA1ESR1
SCHEMBL20119568 0.78 ADORA2A (0.52) PDE5AAPPPDE10AADORA2AADORA1
SCHEMBL20119666 0.75 SMN1; SMN2 (0.57) KCNH3KDRKDM4EALDH1A1LMNA
SCHEMBL20119563 0.75 HRH4 (0.36) ESR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PDE5A 3202/4885APP 604/4885PDE10A 2441/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 PDE5A 3202/4885APP 604/4885PDE10A 2441/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PDE5A 3202/4885APP 604/4885PDE10A 2441/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 PDE5A 3202/4885APP 604/4885PDE10A 2441/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PDE5A 3202/4885APP 604/4885PDE10A 2441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.